The major effort of this section continues to be the refining of existing methodologies for the study of cortical functioning based on positron emission tomography (PET) and to a lesser degree electrical brain mapping procedures particularly as they complement PET information. We continue to contribute to the development and comparison of three methods of data abstraction, the """"""""peel"""""""", the """"""""ring"""""""" and the region of interest (ROI). We have been examining the benefits of standardizing the abstracted PET data to emphasize that information that directly pertains to the activity of localized regions of the brain as opposed to the overall glucose metabolic rate (GMR) of the brain. To accomplish this we have explored multivariate analytical approaches other than that which has been previously used (repeated measures analysis of variance) which we feel is not suitable to the important biomedical questions that PET should be addressing. We have pursued as thorough an analysis as possible of the FDG PET representations of two behavioral paradigms, repeated somatosensory stimuli and an auditory continuous performance test. They complement each other in that in the former the """"""""normal"""""""" response is to habituate to a """"""""benign"""""""" sensory stimulus, whereas the latter task requires selective attention. Differences are observable and suggest that PET is a modality where specific functionally distinct regions of the frontal cortex can be examined. These paradigms are currently in use to study normal habituation and selective attention and to evaluate whether these fundamental processes are altered in mental illness. To date, schizophrenic patients do not show the diminution in electrical response to repetitive somatosensory stimuli observed in normals. These differences appear to be reflected in a different PET pattern of GMR.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Intramural Research (Z01)
Project #
1Z01MH000507-03
Application #
4696355
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
U.S. National Institute of Mental Health
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Cohen, Robert M; Szczepanik, Joanna; McManus, Michael et al. (2006) Hippocampal atrophy in the healthy is initially linear and independent of age. Neurobiol Aging 27:1385-94
Cannon-Spoor, H Eleanor; Levy, James A; Zubenko, George S et al. (2005) Effects of previous major depressive illness on cognition in Alzheimer disease patients. Am J Geriatr Psychiatry 13:312-8
Toyama, Hiroshi; Ye, Daniel; Ichise, Masanori et al. (2005) PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32:593-600
Levy, James A; Bergeson, Judy; Putnam, Karen et al. (2004) Context-specific memory and apolipoprotein E (ApoE) epsilon 4: cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease. J Int Neuropsychol Soc 10:362-70
Sunderland, Trey; Mirza, Nadeem; Putnam, Karen T et al. (2004) Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 56:670-6
Podruchny, Teresa A; Connolly, Catherine; Bokde, Arun et al. (2003) In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 48:39-44
Cohen, Robert M; Podruchny, Teresa A; Bokde, Arun L W et al. (2003) Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. Synapse 49:150-6
Doudet, D J; Holden, J E; Jivan, S et al. (2000) In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism. Synapse 38:105-13
Elkashef, A M; Doudet, D; Bryant, T et al. (2000) 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 100:11-Jan
Wyatt, R J; Henter, I D; Bartko, J J (1999) The long-term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry 46:1092-105

Showing the most recent 10 out of 11 publications